For research use only. We do not sell to patients.
Research lipid catalog

Ionizable Lipid Products

Explore 848 lipid and RNA delivery products. Search the full catalog or browse by research category.

Search covers product name, catalog number, synonyms, available CAS numbers and categories. Spaces, hyphens and common punctuation are ignored. Duplicate legacy records are consolidated under one canonical product result.

8177 products · Showing 7941–7960 · 20 per page
DC Chemicals lipid expertise

Built for ionizable-lipid discovery and RNA delivery research

DC Chemicals supports formulation and delivery research with a broad, searchable portfolio of cationic and ionizable lipids. The current directory brings together 848 unique research-use products, with product specifications, pricing, chemical structures and literature-linked formulation data added as each record is verified.

Our experience spans complex lipid synthesis, purification, analytical release and process development. For custom molecules or larger-scale requirements, our team can discuss route development, technical specifications and scale-up options for the intended research workflow.

Learn about cationic and ionizable lipids →
848unique products in the current searchable directory
Evidence-awareliterature modules appear only after source review
Research supportformulation context, handling guidance and calculators
Proprietary innovation · Co-development · GMP

From proprietary lipid design to GMP-grade custom synthesis

DC Chemicals has independently developed ionizable-lipid structures supported by company-owned intellectual property, and selected proprietary lipid programs have advanced to GMP-stage development.

We welcome joint development with customers—from molecular design and lipid synthesis through route and process development. We can also support custom synthesis of GMP-grade ionizable lipids to agreed technical specifications and quality requirements.

Discuss a co-development project →
Proprietary ionizable-lipid structuresCollaborative molecular designCustom lipid synthesisProcess development and scale-upGMP-grade project support

Cat. No.Product NameField of ApplicationChemical Structure

Cenicriviroc is a dual CCR2/CCR5 antagonist, also inhibits both HIV-1 and HIV-2, and displays potent anti-inflammatory and antiinfective activity.

Cenicriviroc Mesylate
BLU-945Featured

BLU-945(BLU945,BLU 945) is a highly potent and selective EGFR+/T790M/C797S (IC50 of 0.5 nM) and EGFR+/T790M (IC50 of 0.4 nM) inhibitor with >900-fold selectivity over EGFR WT (IC50 of 736.3 nM).

BLU-945
SB-328437Featured

SB-328437 is a potent, selective non-peptide CCR3 antagonist with an IC50 of 4.5 nM.

SB-328437

Sigma‑1 receptor antagonist 1 (compound 137) is a potent and selective sigma-1 receptor (σ1R) antagonist, with a high binding affinity to σ1R receptor (Ki = 1.06 nM). Sigma‑1 receptor antagonist 1 exhibits antineuropathic pain activity and acts as a promising agent for the treatment of neuropathic pain[1].

sigma-1 Receptor antagonist 1
GDC-2394Featured

GDC-2394 is an orally active and selective NLRP3 inhibitor, and also inhibits IL-1β with IC50s of 0.4 μM (human IL-1β) and 0.1 μM (mouse IL-1β). GDC-2394 inhibits NLRP3-induced caspase-1 activity without inhibiting NLRC4-dependent inflammasome activation.

GDC-2394
PLX8394Featured

PLX8394 is a potent and selective Raf inhibitor, with an IC50 of appr 5 nM for BRAFV600E.

PLX8394

β-catenin-IN-2 is a potent β-catenin inhibitor, compound H1B1, extracted from patent US20150374662A1. β-catenin-IN-2 can be used for the study of colorectal cancer.

β-catenin-IN-2
LCS3Featured

LCS3 inhibits glutathione disulfide reductase (GSR) and thioredoxin reductase 1 (TXNRD1) (IC50=3.3 µM and 3.8 µM, respectively) synergistically. LCS3 shows anti-tumor activity, and induces apoptosis. LCS3 can be used in lung adenocarcinoma (LUAD) research.

LCS3
VP-4604Featured

VP-4604 is a potent anti-methicillin-resistant Staphylococcus aureus (MRSA) agent. VP-4604 exhibits significant microbial growth inhibition toward Staphylococcus aureus (ATCC 43300) with MIC of 4-8 µg/mL. VP-4604 inhibits the growth of methicillin‐resistant Staphylococcus aureus with growth inhibition >95%.

VP-4604
ZINC69391Featured

Novel specific Rac1 inhibitor, interferring with the interaction of Rac1 with Dock180, a relevant Rac1 activator in glioma invasion, and to reduce Rac1-GTP levels

ZINC69391
GLN-1062Featured

GLN-1062 (Memogain) is an inactive pro-drug of galantamine, the latter being a plant alkaloid approved for the treatment of mild to moderate Alzheimer's disease.

GLN-1062
Oncrasin 1Featured

Oncrasin 1 is a proapoptotic substance. Induces abnormal nuclear aggregation of PKCι and suppressing RNA transcription. Displays antiproliferative effects against various human tumor cell lines. Shown to inhibit human xenograft growth by 75% in vivo. For the detailed information of Oncrasin 1, the solubility of Oncrasin 1 in water, the solubility of Oncrasin 1 in DMSO, the solubility of Oncrasin 1 in PBS buffer, the animal experiment (test) of Oncrasin 1, the cell expriment (test) of Oncrasin 1, the in vivo, in vitro and clinical trial test of Oncrasin 1, the EC50, IC50,and affinity,of Oncrasin 1, For the detailed information of Oncrasin 1, the solubility of Oncrasin 1 in water, the solubility of Oncrasin 1 in DMSO, the solubility of Oncrasin 1 in PBS buffer, the animal experiment (test) of Oncrasin 1, the cell expriment (test) of Oncrasin 1, the in vivo, in vitro and clinical trial test of Oncrasin 1, the EC50, IC50,and affinity,of Oncrasin 1, Please contact DC Chemicals.

Oncrasin 1
APOL1-IN-1Featured

APOL1-IN-1 is a apolipoprotein L1 (APOL1) inhibitor extracted from patent WO2020131807A1 compound 87. APOL1-IN-1 can be used for the research of focal segmental glomerulosclerosis (FSGS) and non-diabetic kidney disease (NDKD)[1].

APOL1-IN-1
CDDO-EAFeatured

A potent Nrf2 activator that upregulates Nrf2 expression and resulted in translocation of Nrf2 into the nucleus.

CDDO-EA
MCB-613Featured

MCB-613 is a novel and potent stimulator of p160 steroid receptor coactivators (SRCs). It is a Pan-SRCs stimulator.

MCB-613
AliskirenFeatured

The first in a class, potent and highly selective, direct renin inhibitor with IC50 of 0.6 nM; no significant inhibition on Cathepsin D, Cathepsin E, Pepsin and HIV-1 peptidase (> 50 uM); orally bioactive.HypertensionApproved

Aliskiren
SivopixantFeatured

Sivopixant (S-600918) is a potent and selective P2X3 receptor antagonist (P2X3 IC50=4.2 nM; P2X2/3 IC50=1100 nM). Sivopixant shows strong analgesic effect.

Sivopixant

Pimavanserin, also known as ACP-103, is a non-dopaminergic atypical antipsychotic for the treatment of Parkinson's disease psychosis and schizophrenia. Pimavanserin has a unique mechanism of action relative to other antipsychotics, behaving as a selective inverse agonist of the serotonin 5-HT2A receptor, with 40-fold selectivity for this site over the 5-HT2C receptor and no significant affinity or activity at the 5-HT2B receptor or dopamine receptors. It was approved by the FDA to treat hallucinations and delusions associated with psychosis experienced by some people with Parkinson's disease on April 29, 2016.

Pimavanserin tartrate
BI-4924Featured

BI-4924 (BI 4924) is a potent, selective NADH/NAD+-competitive PHGDH inhibitor with IC50 of 2 nM.BI-4924 splays high selectivity against the majority of other dehydrogenase targets.

BI-4924

Page 398 of 409 · Browse all 8177 products

Jump to a product page

Featured literature product: HX1 · DCL0028

HX1 is a hydroxyzine-derived ionizable lipid with acetal-containing tails, studied in lipid nanoparticles for brain mRNA delivery and CRISPR–Cas9 delivery. It was the lead in the reported in vivo brain-delivery screen; evidence is preclinical and formulation-dependent.

Read full formulation and performance →